期刊
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
卷 8, 期 6, 页码 373-383出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X15592586
关键词
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2
资金
- NIHR RM/ICR Biomedical Research Centre
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据